Fisetin is one of the leading senolytic candidates, compounds that selectively clear senescent ('zombie') cells that accumulate with age. Mayo Clinic has multiple ongoing trials.
Fisetin reduced senescent cell burden in multiple tissues, extended median and maximum lifespan in mice (12% increase), and reduced age-related pathology.
Active human trials at Mayo Clinic investigating fisetin's effects on frailty, function, and senescence markers in older adults. Results expected to clarify clinical role.
We prioritize randomised controlled trials and meta-analyses over single observational studies. Animal and in-vitro data are listed as "mechanistic", they suggest direction, not human effect size.
We don't cherry-pick favourable studies, omit conflicting evidence, or cite industry-funded trials without flagging the conflict of interest where known.
The research is one thing, what to take, at what dose, paired with what, is another. We compose stacks that turn the evidence into a daily routine.
Studies referenced are real published research. Summaries are paraphrased for accessibility, for exact methods and full text, click through to PubMed. Educational use only, not medical advice. Consult a qualified clinician before starting any new supplement.